WCRX
Warner Chilcott LimitedNASDAQ
WCRX is defunct.
  • Sep. 27, 2013, 4:23 PM
    • The FTC approves Actavis' (ACT) acquisition of Warner Chilcott (WCRX).
    • As part of the deal, ACT will divest Zenchent Fe, an application for a generic version of Lo Loestrin Fe, an application for a generic version of Atelvia, and an approved application for generic Loestrin 24 Fe. (PR)
    | Sep. 27, 2013, 4:23 PM
  • Sep. 9, 2013, 5:38 PM
    | Sep. 9, 2013, 5:38 PM
  • Sep. 4, 2013, 4:52 PM
    • Warner Chilcott says it's entered into a settlement with Mylan (MYL) to resolve damage claims over its Doryx patent.
    • As a result, WCRX expects to record an incremental charge in the current quarter of $6M.
    • This charge is in addition to the $6M it previously recorded in the quarter ended September 30, 2012, and brings the damage to $12M in total.
    • Payment will be made under the $36M bond posted by the company in September 2011 in connection with the initial filing.
    | Sep. 4, 2013, 4:52 PM
  • Jul. 24, 2013, 4:35 PM
    Warner Chilcott (WCRX): Q2 EPS of $0.92 beats by $0.08. Revenue of $613M (-4% Y/Y) beats by $14.77M. (PR)
    | Jul. 24, 2013, 4:35 PM
  • Jul. 11, 2013, 8:42 AM

    Actavis (ACT) and Warner Chilcott (WCRX) receive a request for additional information from the FTC in connection with Actavis' $8.5B acquisition of Warner Chilcott. The request will extend the waiting period for a decision from the FTC until 30 days after the companies have complied with it, although they still expect to complete the deal in H2. (PR)

    | Jul. 11, 2013, 8:42 AM
  • May 21, 2013, 12:11 PM
    Bernstein analyst Aaron Gal says Mylan (MYL -0.4%) could still bid $22/share for Warner Chilcott (WCRX +2.2%) as the latter's "willingness" to accept an all-share deal from Actavis (ACT +0.6%) might bring others to the table.
    | May 21, 2013, 12:11 PM
  • May 20, 2013, 7:15 AM

    Actavis (ACT) confirms it will buy Warner Chilcott (WCRX) for $8.5B in a stock for stock transaction. The deal will see Warner Chilcott shareholders receive 0.160 shares of the "new" Actavis for each Warner Chilcott share they own. The combined company will become the third-largest specialty pharmaceutical player in the U.S.

    | May 20, 2013, 7:15 AM | 1 Comment
  • May 20, 2013, 7:08 AM
    Shares of Warner Chilcott (WCRX) are halted with news pending.
    | May 20, 2013, 7:08 AM
  • May 17, 2013, 2:34 PM
    Actavis' (ACT +1.5%) pursuit of Warner Chilcott (WCRX +0.5%) may be a way to defend itself from a potential takeovers by Valeant Pharmaceuticals (VRX +2.5%) and Mylan (MYL +2.2%). VRX routinely looks at potential acquisitions, but to date has stayed away from WCRX because of its dwindling pipeline, so a combined ACT/WCRX deal would be out of the picture. And it would be virtually impossible for MYL, with a market value of $11.7B, to buy the combined firm. It already has about $6B in debt and Street estimates put a combined companies near $21B.
    | May 17, 2013, 2:34 PM
  • May 15, 2013, 8:28 PM

    Actavis (ACT), which has rebuffed overtures from both Valeant (VRX) and more recently Mylan (MYL), may soon receive a bid from Novartis (NVS), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling a consolidation scramble in the generic-drug industry, the Journal notes, and ACT — which is also playing the role of acquirer in negotiations with Warner Chilcott (WCRX) — is at the center of the deal-making rumor mill.

    | May 15, 2013, 8:28 PM
  • May 13, 2013, 3:01 PM

    Buckingham joins in on the Warner Chilcott (WCRX +6%)/Activis (ACT -0.3%) lovefest, upping its price target on Warner to $24, adding that it sees the potential for a debt-financing deal as high as $30 per share for the company.

    | May 13, 2013, 3:01 PM
  • May 13, 2013, 8:11 AM

    The sell-side loves the Warner Chilcott/Actavis deal, with Morgan Stanley, UBS, and CRT Capital all giving their blessing. UBS sees 50-60% accretion in 2015 and thinks the deal gets done about $23/share. WCRX +5.1% premarket. ACT  closed Friday at $119.86.

    | May 13, 2013, 8:11 AM
  • May 10, 2013, 3:07 PM
    Shares of Activis (ACT +11.4%) and Warner Chilcott (WCRX +24.2%) both resume trading.
    | May 10, 2013, 3:07 PM
  • May 10, 2013, 3:02 PM

    Shares of Activis (ACT +11.9) and Warner Chilcott (WCRX +11%) both remain halted after confirming they are in merger talks. Shares are due to resume trading shortly.

    | May 10, 2013, 3:02 PM
  • May 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | May 10, 2013, 12:52 PM
  • May 10, 2013, 12:40 PM

    More on Actavis (ACT +6.1%) / Warner Chilcott (WCRX +12.3%): The news comes just weeks after ACT broke off merger talks with Valeant Pharmaceuticals (VRX +0.5%) after balking at the premium it was offered. Now, considering the strength of ACT's recent Q1 report, that deal looks dead. Warner, on the other hand, had disclosed over a year ago that it was pursuing a sale.

    | May 10, 2013, 12:40 PM